Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Boehringer Ingelheim's Ben Venue Labs To Close

The firm will shutter its troubled Ohio plant, affecting 1,100 employees.

by Ann M. Thayer
October 11, 2013 | APPEARED IN VOLUME 91, ISSUE 41

Boehringer Ingelheim, the German pharmaceutical company and contract manufacturer, will close its entire Ben Venue Laboratories operation in Bedford, Ohio, by the end of 2013. In August, the firm said it would close part of the facility and cut 400 jobs. The full closure will affect 1,100 employees.

One of Ben Venue’s major products is Johnson & Johnson’s anticancer drug Doxil, a nanoscale liposomal form of doxorubicin. In late September, J&J warned about likely supply shortages this fall; the shortages may now extend into 2014. The Food & Drug Administration did approve a generic version of Doxil from India’s Sun Pharmaceutical Industries in February.

Boehringer has struggled to keep the Ohio site open after a series of drug quality problems and has been operating since January under a consent decree with FDA. “Despite the ongoing support of the U.S. Food & Drug Administration, the tremendous dedication of employees, and significant investments in facility upgrades, the company cannot return to sustainable production,” Boehringer says.

Given the facility’s age and condition, further improvements would require significant additional investment beyond the $350 million already spent to “overcome the systemic manufacturing challenges.” Keeping the site open also would cost the firm about $700 million over the next five years.

Boehringer says it has notified FDA of its decision and is working to minimize the impact on patients. In particular, the company is looking at ways to continue supplying sterile injectable drugs now made at the plant.



This article has been sent to the following recipient:

Craven Moorehead (October 14, 2013 5:17 PM)
Don't be surprised if this is merely a ploy to leverage the government for grants to open a new facility to manufacture Doxil. Boehringer is merely playing the game to force the hand of the FDA since they are one of two manufacturers of Doxil. What's the government goingo to do? Let people die of cancer becuase a company couldn't sustain profitability?
Kyknoc (April 2, 2014 1:51 PM)
Just called them trying to buy their surplus data center equipment,
said they were doing a internal transfer, so you may be right craven.

Leave A Comment

*Required to comment